Rocket Ventures, a program of the Regional Growth Partnership, has awarded Ignite! grants to three Toledo-based firms. These grants are given to help the companies develop and use technology to create new products or improve processes that have an impact on jobs and revenues in Northwest Ohio.

The latest grants were awarded to ADS Biotechnology, LTD, TechTol Imaging, LLC and DoX Systems LLC.

ADS Biotechnology was established in 2007 by three University of Toledo professors who created a blood-volume replacement product through a patented process developed in research at UT.

The new process maintains blood pressure without leaking into the capillaries in critical-care scenarios to provide positive outcomes for patients whose injuries otherwise would  be fatal.

TechTol Imaging invented a new process to acquire and display rotational 3-D digital images for the Internet.

The process and the company are still in early stages, so the grant will help the inventors prove their theory and stand on the forefront of changing the culture and expectations for Internet imaging.

DoX Systems is an electronic medical records company that has created a suite of products and services that allows physicians in private practice to enhance their offices’ productivity. The company’s source code is compatible with virtually every operating system through a Plug and Play design that could position it to be the primary system for its target market.

Craig Ortega, Ignite! program manager for Rocket Ventures, will work with each company to ensure that they achieve strategic goals and meet specific milestones using the grant money they received.

Rocket Ventures, a division of RGP, is a pre-seed, early-stage venture fund for technology-based companies operating within the state of Ohio.

The fund consists of $15 million in state funding and

$7.5 million in private sector investment.

On the web visit www.rgp.org and click on links for more.

This entry was posted on Friday, June 13th, 2008 at 12:00 am and is filed under TFP Version 1.
You can follow any responses to this entry through the RSS 2.0 feed.
Both comments and pings are currently closed.